Fluoxetine

Generic Name
Fluoxetine
Brand Names
Prozac, Sarafem, Symbyax
Drug Type
Small Molecule
Chemical Formula
C17H18F3NO
CAS Number
54910-89-3
Unique Ingredient Identifier
01K63SUP8D
Background

Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.

Indication

Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar ...

Associated Conditions
Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
Associated Therapies
Maintenance therapy
zerohedge.com
·

Drug Trials Funded By Manufacturers Find 50 Percent Greater Drug Effectiveness

Drug studies funded by manufacturers report 50% higher efficacy; Tamar Oostrom's research suggests sponsors selectively publish favorable trials, affecting drug use and patient outcomes.

Precision Psychiatry and the Mental Health Treatment Revolution

Psychiatry lags in precision medicine compared to oncology; efforts in precision psychiatry aim to improve prognosing, diagnosing, and treating mental illness using advanced technologies like NGS and AI. Challenges include the complexity of the brain and lack of single-gene explanations for mental illnesses. Innovations like Beacon Biosignals' Dreem 3 headband for sleep monitoring and Gate Neurosciences' precision neuroscience platform for targeted therapies are advancing the field. The future may see a shift from traditional DSM diagnoses to more personalized, data-driven approaches, potentially reducing stigma and improving patient outcomes.
eurekalert.org
·

Bias found when drug manufacturers fund clinical trials

Psychiatric drugs show 50% higher efficacy in trials funded by manufacturers, attributed to 'sponsorship effect' and publication bias, according to a study by Tamar Oostrom. The study, published in the Journal of Political Economy, analyzed double-blind RCTs and found that adding unpublished trials reduced the sponsorship effect by 20%, indicating most of the effect is due to publication bias. Preregistration has helped reduce this bias since 2005, but it doesn't address past approvals based on potentially biased evidence.
afr.com
·

GLP-1: Why Eli Lilly could be the real weight loss drug winner

Eli Lilly poised to become world's first $1 trillion drugmaker due to Wall Street's interest in weight-loss drugs, despite past challenges when patents for blockbuster psychiatric drugs expired.
healio.com
·

The inside story of Cobenfy

The FDA's approval of Cobenfy (KarXT) marks a significant milestone in psychopharmacology as the first antipsychotic not targeting dopamine 2 receptors. The drug's journey began with xanomeline, synthesized by Novo Nordisk in the 1980s, showing promise in Alzheimer's and schizophrenia studies but shelved by Eli Lilly. Resurrected by Steven M. Paul, MD, who combined it with trospium at Karuna, the drug's approval highlights the industry's potential lapses in foresight and unnecessary delays in bringing effective treatments to market.

Psilocybin Provides Comparable Long-Term Antidepressant Effects as SSRIs

A study at ECNP Congress in Milan found psilocybin, from 'magic mushrooms,' as effective as escitalopram in treating depression, with potential long-term benefits. Psilocybin users reported better psychosocial functioning and life meaning over six months. Psilocybin could offer an alternative for non-responders to SSRIs, though its use requires controlled environments.
drugs.com
·

Psilocybin Equals or Exceeds SSRI Antidepressants at Easing Depression

Psilocybin, in magic mushrooms, shows similar depression relief to SSRI antidepressants like Lexapro, with additional long-term benefits of greater life meaning and psychological connectedness, according to a clinical trial. However, psilocybin is experimental and should not be self-administered.
eurekalert.org
·

Study shows psychedelic drug psilocybin gives

Psilocybin and SSRI escitalopram showed similar long-term depression symptom improvements, but psilocybin offered additional benefits in psychosocial functioning, meaning in life, and psychological connectedness over 6 months. Psilocybin also improved sexual drive, unlike SSRIs, suggesting potential additional mental health benefits.
statnews.com
·

End the 'forced swim test' on mice for antidepressant research

The forced swim test (FST) and tail suspension test (TST) are criticized for inaccurately modeling human depression, leading to ineffective antidepressant development. Despite being deemed invalid for 15 years, these tests continue to be funded and published, despite evidence suggesting they are not reliable predictors of human responses to antidepressants. The UK and Australia have banned the FST, and the NIH is shifting towards non-animal-based research methods. An upcoming advisory council meeting could be pivotal in ending the use of these outdated tests.
© Copyright 2024. All Rights Reserved by MedPath